Allogeneic Mesenchymal Stromal Cells is under clinical development by Pandorum International and currently in Phase I for Pneumonia. According to GlobalData, Phase I drugs for Pneumonia have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Allogeneic Mesenchymal Stromal Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Allogeneic Mesenchymal Stromal Cells overview

Cell therapy is under development for the treatment of coronavirus disease 2019 (covid-19) pneumonia and other viral pneumonias. The therapeutic candidate comprises of allogenic mesenchymal stromal cells derived human umbilical cord. It is administered by intravenous route.

Pandorum International overview

Pandorum International operate in healthcare sector. Pandorum International is headquartered in San Carlos, California, the US.

For a complete picture of Allogeneic Mesenchymal Stromal Cells’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.